Prognostic and Predictive Value of P53


Book Description

Hardbound. This first volume in the series, European School of Oncology Scientific Updates, deals with one of the most important genes in the molecular genetics of human cancer: p53.This cellular protein was discovered in 1979 by a number of investigators independently and alterations of p53 or its product are observed in about half of all cancers.In the early 1980s, several laboratories initially demonstrated dominant oncogenic activities of the gene. Then, in 1989, p53 was recognised as a classic tumour suppressor gene based on the results of various studies by different research groups.Since the detection of the gene and its product, various important functions have been described. The gene appears to be involved in cell cycle control, DNA repair, apoptosis, cellular differentiation, senescence and angiogenesis.In view of the rapidly increasing importance of p53, a Task Force Meeting was organised by the European School of Oncology




Systems Biology of Cancer


Book Description

An overview of the current systems biology-based knowledge and the experimental approaches for deciphering the biological basis of cancer.




Prognostic variables in node-negative and node-positive breast cancer


Book Description

During the last decade, important advancements on the understanding of the molecular mechanisms involved in tumorigenesis and progression of breast cancer have been made, particularly regarding the mechanisms of control of the cell cycle, apoptosis, metastasis, and angiogenesis. Translation of basic research to the clinical setting by the identification of assessable markers associated with the above biological mechanisms has permitted verification of the clinical significance of several prognostic indicators and has highlighted the heterogeneous nature of invasive breast cancer.Reprinted from Breast Cancer Research And Treatment, this text contains original papers, overviews, and position papers on the methodological aspects and the clinical significance of the more interesting prognostic and predictive indicators. Ultimately, the determination of biological prognostic and predictive markers with easily applicable, reproducible, and standardizable assays is an integral part of future research aimed to improve the management of patients operated for breast cancer in the years to come. Novel therapeutic strategies based not only on chemotherapy or hormone therapy, but directed at interfering with the molecular targets involved in tumor progression and metastasis, warrant clinical testing and are a major challenge to enhance the potential cure of breast cancer.




25 Years of p53 Research


Book Description

p53 has emerged as a key tumor suppressor and important target for novel cancer therapy. This book, written by world-leading p53 researchers including many of those who have shaped the field over the past 25 years, provides unique insights into the progress of the field and the prospects for better cancer diagnosis and therapy in the future.




Precision Medicine in Oncology


Book Description

A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.




Prognosis Research in Healthcare


Book Description

"What is going to happen to me?" Most patients ask this question during a clinical encounter with a health professional. As well as learning what problem they have (diagnosis) and what needs to be done about it (treatment), patients want to know about their future health and wellbeing (prognosis). Prognosis research can provide answers to this question and satisfy the need for individuals to understand the possible outcomes of their condition, with and without treatment. Central to modern medical practise, the topic of prognosis is the basis of decision making in healthcare and policy development. It translates basic and clinical science into practical care for patients and populations. Prognosis Research in Healthcare: Concepts, Methods and Impact provides a comprehensive overview of the field of prognosis and prognosis research and gives a global perspective on how prognosis research and prognostic information can improve the outcomes of healthcare. It details how to design, carry out, analyse and report prognosis studies, and how prognostic information can be the basis for tailored, personalised healthcare. In particular, the book discusses how information about the characteristics of people, their health, and environment can be used to predict an individual's future health. Prognosis Research in Healthcare: Concepts, Methods and Impact, addresses all types of prognosis research and provides a practical step-by-step guide to undertaking and interpreting prognosis research studies, ideal for medical students, health researchers, healthcare professionals and methodologists, as well as for guideline and policy makers in healthcare wishing to learn more about the field of prognosis.




p53 in the Clinics


Book Description

This project follows on the success of the book "25 years of p53", published by Springer in 2006. Since this publication, there have been considerable advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".







Biomarkers in Breast Cancer


Book Description

Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.




Glioblastomas: New Insights for the Healthcare Professional: 2011 Edition


Book Description

Glioblastomas: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Glioblastomas. The editors have built Glioblastomas: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Glioblastomas in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Glioblastomas: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.